Immunicum – executive interview

Immunicum – executive interview

Mendus — 3 videos in collection

More on this equity

Immunicum is a clinical-stage immunoncology company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumours. Its lead clinical asset in development (Phase II, acute myeloid leukaemia) is based on intratumoural priming and cancer relapse vaccination.
In this video, the company’s chief executive officer, Erik Manting, provides an overview of the company’s strategy and differentiated approach.

You may also be interested in these:

Screenshot 2023-11-27 080035


Mendus – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free